In a webinar, clinical oncologists spoke about the ways that their treatment practices and workplaces have had to change during the coronavirus disease 2019 pandemic and the ways they should continue to change.
The researchers indicated that the results could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.
According to researchers, black and Hispanic patients are less likely to undergo guideline recommended PET/CT imaging at NSCLC diagnosis, which could partially explain differences in survival.
The FDA has approved a 420 mg multi-dose vial of trastuzumab-dttb (Ontruzant), a biosimilar referencing trastuzumab (Herceptin).
The FDA Oncology Center of Excellence put out a statement regarding patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic and how they are prioritizing their care.
In this study, researchers found that endoscopic therapy was the most effective strategy for patients with T1 CRC with less aggressive biomarker profiles and laparoscopic colectomy was the most effective for patients with more aggressive profiles.
Adults with advanced non-small cell lung cancer and impaired performance status experience significantly shorter survival after treatment with immune checkpoint inhibitors (ICIs) and receive ICIs more often than those with better performance status.
Breast cancer incidence in women aged 25 to 39 has been steadily increasing for the last 80 years, though researchers indicated that this increase cannot be attributed to changes in parity over time.
Though inflammatory bowel disease patients are generally at higher risk of HPV-related cancers, this data did not support intensified screening for vulvar or vaginal malignancies in female IBD patients.
The study also suggested that palliative care is rarely consulted for highly symptomatic patients with possibly curable cancer, highlighting the need for supportive care interventions.